Discover the groundbreaking Gut-Kidney Axis Chip, designed to study Shiga toxin-producing E. coli (STEC) infections and their impact on kidney damage. Our research reveals that while ciprofloxacin (CIP) reduces infection, it increases the risk of hemolytic-uremic syndrome (HUS), a severe kidney condition. In contrast, gentamicin effectively combats infection and mitigates kidney damage, offering vital insights into antibiotic effects on HUS risk. Explore our website to learn how the Gut-Kidney Axis Chip advances understanding of STEC infections and guides improved treatment strategies.